<p>New Delhi: Dr Reddy's Laboratories on Friday reported a 33.02 per cent increase in consolidated profit after tax at Rs 1,482.2 crore in the second quarter ended September 30, led by the US generics market.</p>.<p> The company had posted a consolidated profit after tax of Rs 1,114.2 crore in the same quarter a year ago, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.</p>.<p> The consolidated total revenue from operations was at Rs 6,902.6 crore, up 9 per cent, compared to Rs 6,331.8 crore in the year-ago period.</p>.<p> DRL's total expenses in the September quarter were up 11.14 per cent to Rs 5,305.1 crore.</p>.<p> Total income of DRL in the September quarter was at Rs 7,217.6 crore, up 13.25 per cent.</p>.<p> "We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe."</p>.<p> “We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation," Co-Chairman & MD, G V Prasad said.</p>.Maruti Suzuki India smashes Q2 profit view on SUV demand.<p> DRL's global generics posted a revenue of Rs 6,113 crore in Q2, up 9.14 per cent from the year-ago quarter, driven by North America, emerging markets and Europe.</p>.<p> North America's revenue was at Rs 3,170 crore, a growth of 13 per cent, while that of Europe was at Rs 528.6 crore, with a growth of 26 per cent, the company said.</p>.<p> While its revenue from 'Pharmaceutical Services and Active Ingredients' was at Rs 962.5 crore, up 16.95 per cent, as against Rs 823 crore, a year before.</p>.<p> Shares of Dr Reddy's Laboratories Ltd on Friday settled at Rs 5,385.55 on BSE, down 0.72 per cent from the previous close. </p>
<p>New Delhi: Dr Reddy's Laboratories on Friday reported a 33.02 per cent increase in consolidated profit after tax at Rs 1,482.2 crore in the second quarter ended September 30, led by the US generics market.</p>.<p> The company had posted a consolidated profit after tax of Rs 1,114.2 crore in the same quarter a year ago, Dr Reddy's Laboratories Ltd (DRL) said in a regulatory filing.</p>.<p> The consolidated total revenue from operations was at Rs 6,902.6 crore, up 9 per cent, compared to Rs 6,331.8 crore in the year-ago period.</p>.<p> DRL's total expenses in the September quarter were up 11.14 per cent to Rs 5,305.1 crore.</p>.<p> Total income of DRL in the September quarter was at Rs 7,217.6 crore, up 13.25 per cent.</p>.<p> "We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe."</p>.<p> “We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation," Co-Chairman & MD, G V Prasad said.</p>.Maruti Suzuki India smashes Q2 profit view on SUV demand.<p> DRL's global generics posted a revenue of Rs 6,113 crore in Q2, up 9.14 per cent from the year-ago quarter, driven by North America, emerging markets and Europe.</p>.<p> North America's revenue was at Rs 3,170 crore, a growth of 13 per cent, while that of Europe was at Rs 528.6 crore, with a growth of 26 per cent, the company said.</p>.<p> While its revenue from 'Pharmaceutical Services and Active Ingredients' was at Rs 962.5 crore, up 16.95 per cent, as against Rs 823 crore, a year before.</p>.<p> Shares of Dr Reddy's Laboratories Ltd on Friday settled at Rs 5,385.55 on BSE, down 0.72 per cent from the previous close. </p>